| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 97 | 2025 | 473 | 32.890 |
Why?
|
| Myocardial Infarction | 89 | 2025 | 1044 | 15.930 |
Why?
|
| Platelet Aggregation Inhibitors | 81 | 2025 | 462 | 15.720 |
Why?
|
| Rivaroxaban | 27 | 2024 | 255 | 9.320 |
Why?
|
| Aspirin | 32 | 2024 | 387 | 7.570 |
Why?
|
| Stroke | 41 | 2024 | 1133 | 6.760 |
Why?
|
| Acute Coronary Syndrome | 34 | 2024 | 275 | 6.410 |
Why?
|
| Lactones | 24 | 2022 | 56 | 6.220 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 27 | 2025 | 66 | 6.020 |
Why?
|
| Fibrinolytic Agents | 17 | 2025 | 271 | 5.960 |
Why?
|
| Secondary Prevention | 44 | 2025 | 233 | 5.820 |
Why?
|
| Lower Extremity | 26 | 2025 | 423 | 5.800 |
Why?
|
| Thrombosis | 21 | 2024 | 366 | 5.700 |
Why?
|
| Adenosine | 20 | 2023 | 225 | 5.530 |
Why?
|
| Pyridines | 27 | 2022 | 506 | 5.480 |
Why?
|
| Vascular Surgical Procedures | 14 | 2024 | 299 | 5.070 |
Why?
|
| Factor Xa Inhibitors | 16 | 2024 | 172 | 4.930 |
Why?
|
| Atherosclerosis | 22 | 2025 | 415 | 4.930 |
Why?
|
| Ischemia | 27 | 2025 | 407 | 4.930 |
Why?
|
| Endovascular Procedures | 13 | 2025 | 315 | 4.560 |
Why?
|
| Diabetes Mellitus, Type 2 | 28 | 2025 | 2518 | 4.440 |
Why?
|
| Hemorrhage | 45 | 2025 | 721 | 4.330 |
Why?
|
| Coronary Artery Disease | 18 | 2025 | 698 | 3.930 |
Why?
|
| Treatment Outcome | 103 | 2025 | 10748 | 3.760 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2024 | 443 | 3.560 |
Why?
|
| Cardiovascular Diseases | 30 | 2025 | 2105 | 3.360 |
Why?
|
| Aged | 139 | 2025 | 23808 | 3.070 |
Why?
|
| Humans | 285 | 2025 | 136803 | 3.000 |
Why?
|
| Troponin I | 10 | 2022 | 81 | 2.930 |
Why?
|
| Venous Thromboembolism | 13 | 2025 | 313 | 2.930 |
Why?
|
| Heart Failure | 24 | 2025 | 2231 | 2.860 |
Why?
|
| Drug Therapy, Combination | 28 | 2025 | 1062 | 2.820 |
Why?
|
| Risk Factors | 80 | 2025 | 10332 | 2.790 |
Why?
|
| Anticholesteremic Agents | 7 | 2024 | 153 | 2.700 |
Why?
|
| Double-Blind Method | 48 | 2025 | 1982 | 2.600 |
Why?
|
| Aortic Diseases | 5 | 2022 | 117 | 2.600 |
Why?
|
| Middle Aged | 125 | 2025 | 33239 | 2.500 |
Why?
|
| Brain Ischemia | 8 | 2022 | 340 | 2.500 |
Why?
|
| Thrombolytic Therapy | 8 | 2021 | 145 | 2.300 |
Why?
|
| Drug-Eluting Stents | 5 | 2025 | 81 | 2.280 |
Why?
|
| Anticoagulants | 18 | 2025 | 664 | 2.280 |
Why?
|
| Male | 154 | 2025 | 67330 | 2.140 |
Why?
|
| Randomized Controlled Trials as Topic | 25 | 2025 | 1462 | 2.100 |
Why?
|
| Dyslipidemias | 5 | 2025 | 176 | 2.090 |
Why?
|
| Stroke Volume | 11 | 2025 | 612 | 2.070 |
Why?
|
| Female | 151 | 2025 | 72816 | 2.000 |
Why?
|
| Risk Assessment | 34 | 2025 | 3434 | 1.980 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2025 | 612 | 1.970 |
Why?
|
| Atrial Fibrillation | 7 | 2025 | 389 | 1.950 |
Why?
|
| Glucagon-Like Peptides | 3 | 2025 | 56 | 1.930 |
Why?
|
| Diabetes Mellitus | 11 | 2023 | 1033 | 1.900 |
Why?
|
| Walking | 8 | 2025 | 523 | 1.880 |
Why?
|
| Cholesterol, LDL | 7 | 2024 | 366 | 1.840 |
Why?
|
| Ventricular Function, Left | 5 | 2025 | 533 | 1.710 |
Why?
|
| Hypoglycemic Agents | 13 | 2025 | 1283 | 1.660 |
Why?
|
| Intermittent Claudication | 7 | 2025 | 118 | 1.640 |
Why?
|
| Glucosides | 8 | 2020 | 44 | 1.600 |
Why?
|
| Hospitalization | 15 | 2025 | 2184 | 1.590 |
Why?
|
| Benzhydryl Compounds | 8 | 2020 | 73 | 1.560 |
Why?
|
| ST Elevation Myocardial Infarction | 6 | 2025 | 54 | 1.540 |
Why?
|
| Hypolipidemic Agents | 3 | 2025 | 92 | 1.470 |
Why?
|
| Blood Coagulation Disorders | 2 | 2023 | 172 | 1.360 |
Why?
|
| Percutaneous Coronary Intervention | 8 | 2025 | 478 | 1.300 |
Why?
|
| Embolism | 2 | 2022 | 41 | 1.290 |
Why?
|
| Time Factors | 35 | 2025 | 6809 | 1.250 |
Why?
|
| Troponin T | 6 | 2022 | 67 | 1.240 |
Why?
|
| Extremities | 6 | 2021 | 129 | 1.190 |
Why?
|
| Follow-Up Studies | 28 | 2025 | 5106 | 1.180 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 25 | 1.170 |
Why?
|
| Biomarkers | 31 | 2025 | 4145 | 1.140 |
Why?
|
| International Classification of Diseases | 2 | 2025 | 132 | 1.080 |
Why?
|
| Piperazines | 8 | 2014 | 350 | 1.050 |
Why?
|
| Receptors, Thrombin | 5 | 2015 | 13 | 1.050 |
Why?
|
| Postoperative Complications | 3 | 2024 | 2639 | 1.020 |
Why?
|
| Limb Salvage | 8 | 2025 | 54 | 1.000 |
Why?
|
| Vascular Diseases | 4 | 2023 | 243 | 0.990 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 5 | 0.990 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2024 | 888 | 0.980 |
Why?
|
| Sterol O-Acyltransferase | 2 | 2022 | 5 | 0.970 |
Why?
|
| Electrocardiography | 8 | 2018 | 629 | 0.970 |
Why?
|
| Cardiovascular Agents | 4 | 2022 | 160 | 0.950 |
Why?
|
| Myocardial Ischemia | 6 | 2021 | 262 | 0.930 |
Why?
|
| Hypercholesterolemia | 2 | 2024 | 105 | 0.930 |
Why?
|
| Blood Glucose | 2 | 2025 | 2181 | 0.920 |
Why?
|
| Incretins | 1 | 2025 | 22 | 0.920 |
Why?
|
| Incidence | 17 | 2025 | 2797 | 0.910 |
Why?
|
| Mobile Applications | 2 | 2024 | 182 | 0.900 |
Why?
|
| Community Health Workers | 1 | 2025 | 62 | 0.900 |
Why?
|
| Prasugrel Hydrochloride | 6 | 2024 | 22 | 0.890 |
Why?
|
| Kidney Diseases | 5 | 2020 | 407 | 0.880 |
Why?
|
| Hyperglycemia | 2 | 2025 | 347 | 0.870 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2023 | 82 | 0.840 |
Why?
|
| Chest Pain | 4 | 2017 | 92 | 0.840 |
Why?
|
| Cardiology | 3 | 2022 | 274 | 0.840 |
Why?
|
| Acute Disease | 8 | 2021 | 1007 | 0.820 |
Why?
|
| Acetanilides | 6 | 2014 | 11 | 0.820 |
Why?
|
| Recurrence | 21 | 2024 | 1055 | 0.800 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 3 | 0.790 |
Why?
|
| Antifibrinolytic Agents | 1 | 2023 | 51 | 0.790 |
Why?
|
| Patient Selection | 3 | 2022 | 691 | 0.790 |
Why?
|
| Prospective Studies | 22 | 2025 | 7573 | 0.770 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 4 | 2025 | 12 | 0.770 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2025 | 255 | 0.770 |
Why?
|
| Multicenter Studies as Topic | 8 | 2025 | 308 | 0.760 |
Why?
|
| Outpatients | 3 | 2024 | 393 | 0.750 |
Why?
|
| United States | 25 | 2025 | 14691 | 0.750 |
Why?
|
| Medicare | 9 | 2024 | 758 | 0.720 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2020 | 47 | 0.720 |
Why?
|
| Paclitaxel | 2 | 2021 | 227 | 0.720 |
Why?
|
| Disease Management | 2 | 2024 | 624 | 0.700 |
Why?
|
| Beneficence | 1 | 2021 | 17 | 0.700 |
Why?
|
| Proprotein Convertase 9 | 6 | 2021 | 73 | 0.700 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 96 | 0.700 |
Why?
|
| Biomedical Research | 2 | 2025 | 688 | 0.700 |
Why?
|
| Databases, Factual | 5 | 2024 | 1351 | 0.700 |
Why?
|
| Platelet Aggregation | 5 | 2023 | 100 | 0.690 |
Why?
|
| Myocarditis | 2 | 2019 | 100 | 0.690 |
Why?
|
| Quality of Life | 5 | 2025 | 2878 | 0.690 |
Why?
|
| Research Subjects | 1 | 2021 | 41 | 0.690 |
Why?
|
| Prognosis | 16 | 2025 | 4013 | 0.690 |
Why?
|
| Dyspnea | 2 | 2020 | 254 | 0.680 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 7593 | 0.680 |
Why?
|
| Personal Autonomy | 1 | 2021 | 49 | 0.680 |
Why?
|
| Hypertension | 4 | 2025 | 1285 | 0.670 |
Why?
|
| Diabetes Complications | 2 | 2021 | 226 | 0.670 |
Why?
|
| Renal Insufficiency | 2 | 2021 | 155 | 0.660 |
Why?
|
| Beverages | 1 | 2020 | 69 | 0.650 |
Why?
|
| Sex Characteristics | 2 | 2023 | 763 | 0.650 |
Why?
|
| Cholesterol | 4 | 2022 | 410 | 0.650 |
Why?
|
| Lipoproteins, HDL | 4 | 2024 | 77 | 0.650 |
Why?
|
| Caffeine | 1 | 2020 | 68 | 0.640 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2025 | 99 | 0.640 |
Why?
|
| Informed Consent | 1 | 2021 | 172 | 0.640 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2025 | 133 | 0.640 |
Why?
|
| Leg | 1 | 2021 | 236 | 0.630 |
Why?
|
| Patient Care Team | 1 | 2024 | 626 | 0.610 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2020 | 131 | 0.600 |
Why?
|
| Ezetimibe | 1 | 2018 | 24 | 0.600 |
Why?
|
| Syndrome | 5 | 2023 | 357 | 0.600 |
Why?
|
| Pyrimidines | 4 | 2025 | 470 | 0.590 |
Why?
|
| Stents | 4 | 2021 | 528 | 0.590 |
Why?
|
| Consensus | 2 | 2022 | 678 | 0.580 |
Why?
|
| Drug Administration Schedule | 10 | 2024 | 785 | 0.560 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 328 | 0.560 |
Why?
|
| Blood Platelets | 5 | 2023 | 407 | 0.560 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2021 | 2052 | 0.550 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 562 | 0.550 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2023 | 40 | 0.540 |
Why?
|
| Proportional Hazards Models | 11 | 2021 | 1262 | 0.530 |
Why?
|
| Neoplasms | 3 | 2023 | 2643 | 0.530 |
Why?
|
| Medical Oncology | 1 | 2019 | 288 | 0.520 |
Why?
|
| Cause of Death | 8 | 2024 | 430 | 0.520 |
Why?
|
| Survival Rate | 6 | 2021 | 1964 | 0.520 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2025 | 54 | 0.520 |
Why?
|
| Heparin | 3 | 2023 | 259 | 0.510 |
Why?
|
| Smoking Cessation | 2 | 2024 | 436 | 0.510 |
Why?
|
| Enzyme Inhibitors | 5 | 2014 | 839 | 0.490 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2018 | 185 | 0.490 |
Why?
|
| Patient Readmission | 1 | 2021 | 694 | 0.480 |
Why?
|
| Ulcer | 2 | 2021 | 32 | 0.470 |
Why?
|
| Hematoma | 2 | 2021 | 53 | 0.470 |
Why?
|
| Angioplasty, Balloon | 4 | 2025 | 93 | 0.460 |
Why?
|
| Ankle Brachial Index | 5 | 2025 | 37 | 0.460 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2019 | 21 | 0.450 |
Why?
|
| Pragmatic Clinical Trials as Topic | 3 | 2025 | 64 | 0.450 |
Why?
|
| Benzazepines | 3 | 2019 | 39 | 0.450 |
Why?
|
| Apolipoprotein A-I | 2 | 2024 | 30 | 0.440 |
Why?
|
| Thiophenes | 2 | 2011 | 117 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1430 | 0.430 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2019 | 36 | 0.430 |
Why?
|
| Global Health | 4 | 2021 | 385 | 0.400 |
Why?
|
| Ranolazine | 7 | 2014 | 25 | 0.400 |
Why?
|
| Lecithins | 2 | 2022 | 5 | 0.390 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 14 | 0.390 |
Why?
|
| Intracranial Hemorrhages | 5 | 2018 | 85 | 0.390 |
Why?
|
| Life Style | 1 | 2015 | 487 | 0.390 |
Why?
|
| Venous Thrombosis | 3 | 2025 | 190 | 0.390 |
Why?
|
| Comorbidity | 4 | 2025 | 1614 | 0.390 |
Why?
|
| Receptor, PAR-1 | 5 | 2019 | 16 | 0.380 |
Why?
|
| MicroRNAs | 3 | 2023 | 692 | 0.380 |
Why?
|
| Retrospective Studies | 11 | 2025 | 15510 | 0.370 |
Why?
|
| Cohort Studies | 10 | 2022 | 5704 | 0.370 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2023 | 195 | 0.370 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 143 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2668 | 0.360 |
Why?
|
| Enoxaparin | 2 | 2021 | 63 | 0.350 |
Why?
|
| Exercise Therapy | 4 | 2025 | 436 | 0.340 |
Why?
|
| Thrombin | 3 | 2021 | 152 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 801 | 0.340 |
Why?
|
| Angina Pectoris | 2 | 2009 | 65 | 0.330 |
Why?
|
| Clinical Trials as Topic | 5 | 2025 | 1044 | 0.330 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2009 | 140 | 0.320 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2021 | 105 | 0.320 |
Why?
|
| Exercise Tolerance | 2 | 2025 | 279 | 0.310 |
Why?
|
| Appetite Depressants | 2 | 2019 | 18 | 0.300 |
Why?
|
| Absorbable Implants | 2 | 2025 | 35 | 0.290 |
Why?
|
| Thromboembolism | 3 | 2024 | 119 | 0.290 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 233 | 0.290 |
Why?
|
| Troponin | 3 | 2020 | 50 | 0.290 |
Why?
|
| Exercise | 2 | 2021 | 2044 | 0.290 |
Why?
|
| Hospital Mortality | 3 | 2021 | 901 | 0.280 |
Why?
|
| Risk | 5 | 2019 | 908 | 0.280 |
Why?
|
| Europe | 3 | 2021 | 413 | 0.280 |
Why?
|
| Adult | 21 | 2025 | 37643 | 0.280 |
Why?
|
| Ticlopidine | 5 | 2016 | 52 | 0.280 |
Why?
|
| Prevalence | 6 | 2025 | 2710 | 0.280 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2018 | 46 | 0.270 |
Why?
|
| Factor XI | 2 | 2024 | 9 | 0.270 |
Why?
|
| American Heart Association | 3 | 2022 | 306 | 0.270 |
Why?
|
| Registries | 7 | 2025 | 2015 | 0.270 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 354 | 0.260 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 1231 | 0.260 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 188 | 0.260 |
Why?
|
| Chronic Disease | 4 | 2025 | 1786 | 0.260 |
Why?
|
| Ventricular Function | 1 | 2006 | 61 | 0.260 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 745 | 0.250 |
Why?
|
| Popliteal Artery | 2 | 2023 | 59 | 0.250 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 2822 | 0.250 |
Why?
|
| Internationality | 3 | 2022 | 154 | 0.250 |
Why?
|
| Telemedicine | 2 | 2025 | 852 | 0.250 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2023 | 33 | 0.240 |
Why?
|
| Diabetic Nephropathies | 2 | 2019 | 294 | 0.240 |
Why?
|
| Saphenous Vein | 1 | 2025 | 35 | 0.230 |
Why?
|
| Peptide Fragments | 2 | 2023 | 705 | 0.230 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 5424 | 0.230 |
Why?
|
| Colorado | 2 | 2025 | 4515 | 0.230 |
Why?
|
| Obesity | 4 | 2019 | 2982 | 0.230 |
Why?
|
| Aminobutyrates | 1 | 2025 | 35 | 0.230 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2025 | 80 | 0.230 |
Why?
|
| Pulmonary Embolism | 2 | 2025 | 225 | 0.230 |
Why?
|
| Recovery of Function | 3 | 2025 | 652 | 0.230 |
Why?
|
| Injections, Subcutaneous | 1 | 2025 | 154 | 0.230 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 64 | 0.230 |
Why?
|
| Pravastatin | 2 | 2016 | 41 | 0.230 |
Why?
|
| Walk Test | 1 | 2025 | 76 | 0.220 |
Why?
|
| Angiography | 2 | 2024 | 207 | 0.220 |
Why?
|
| Immunotherapy | 2 | 2019 | 640 | 0.220 |
Why?
|
| Cardiovascular System | 2 | 2022 | 137 | 0.220 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 174 | 0.220 |
Why?
|
| Heptanoic Acids | 2 | 2015 | 66 | 0.210 |
Why?
|
| Angioplasty | 1 | 2023 | 47 | 0.210 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2023 | 4 | 0.210 |
Why?
|
| Angina, Unstable | 3 | 2013 | 76 | 0.210 |
Why?
|
| Arteries | 2 | 2022 | 269 | 0.210 |
Why?
|
| Thromboplastin | 1 | 2023 | 74 | 0.210 |
Why?
|
| Age Factors | 5 | 2024 | 3286 | 0.200 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 125 | 0.200 |
Why?
|
| Echocardiography | 2 | 2024 | 643 | 0.200 |
Why?
|
| Pyrroles | 2 | 2015 | 213 | 0.200 |
Why?
|
| Pyridones | 1 | 2024 | 168 | 0.190 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1936 | 0.190 |
Why?
|
| Liraglutide | 1 | 2022 | 30 | 0.190 |
Why?
|
| Thiazoles | 1 | 2022 | 123 | 0.190 |
Why?
|
| Coronary Angiography | 1 | 2024 | 311 | 0.190 |
Why?
|
| Numbers Needed To Treat | 1 | 2021 | 7 | 0.190 |
Why?
|
| Symporters | 1 | 2022 | 66 | 0.190 |
Why?
|
| Mobility Limitation | 1 | 2022 | 61 | 0.190 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 2022 | 0.180 |
Why?
|
| Kidney | 2 | 2020 | 1467 | 0.180 |
Why?
|
| Doxorubicin | 1 | 2023 | 362 | 0.180 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 348 | 0.180 |
Why?
|
| Warfarin | 1 | 2022 | 153 | 0.180 |
Why?
|
| Inflammation | 3 | 2023 | 2835 | 0.180 |
Why?
|
| Frailty | 1 | 2024 | 170 | 0.180 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 17 | 0.180 |
Why?
|
| Myocardial Revascularization | 4 | 2021 | 73 | 0.180 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2023 | 202 | 0.180 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 229 | 0.180 |
Why?
|
| Lipids | 1 | 2025 | 665 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2025 | 426 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 225 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2025 | 817 | 0.170 |
Why?
|
| Rural Population | 1 | 2025 | 561 | 0.170 |
Why?
|
| Medication Adherence | 1 | 2024 | 468 | 0.170 |
Why?
|
| Placebos | 1 | 2021 | 199 | 0.170 |
Why?
|
| Drug Therapy | 1 | 2021 | 84 | 0.170 |
Why?
|
| Heart Diseases | 2 | 2016 | 346 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 190 | 0.170 |
Why?
|
| Genetic Variation | 1 | 2025 | 985 | 0.170 |
Why?
|
| Methylamines | 1 | 2020 | 34 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2014 | 1321 | 0.160 |
Why?
|
| Blood Coagulation | 1 | 2021 | 255 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2025 | 1693 | 0.160 |
Why?
|
| Glucagon-Like Peptide Receptors | 1 | 2019 | 1 | 0.160 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2019 | 41 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 3265 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 179 | 0.160 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 67 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 215 | 0.160 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 63 | 0.160 |
Why?
|
| Heart | 1 | 2023 | 653 | 0.160 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 88 | 0.160 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 6 | 0.150 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 761 | 0.150 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2009 | 24 | 0.150 |
Why?
|
| Bone Density Conservation Agents | 1 | 2019 | 80 | 0.150 |
Why?
|
| Appetite Regulation | 1 | 2019 | 31 | 0.150 |
Why?
|
| Microcirculation | 1 | 2019 | 146 | 0.150 |
Why?
|
| Pharmacovigilance | 1 | 2018 | 23 | 0.150 |
Why?
|
| Hemoglobins | 1 | 2021 | 353 | 0.150 |
Why?
|
| Cardiac Rehabilitation | 1 | 2019 | 37 | 0.150 |
Why?
|
| Weight Loss | 3 | 2019 | 776 | 0.150 |
Why?
|
| Drug Approval | 2 | 2019 | 87 | 0.150 |
Why?
|
| Adamantane | 1 | 2018 | 18 | 0.150 |
Why?
|
| Coronary Disease | 2 | 2018 | 384 | 0.150 |
Why?
|
| Dipeptides | 1 | 2018 | 50 | 0.150 |
Why?
|
| Platelet Activation | 2 | 2017 | 93 | 0.150 |
Why?
|
| Canagliflozin | 1 | 2018 | 10 | 0.150 |
Why?
|
| Reoperation | 1 | 2021 | 573 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 640 | 0.150 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2018 | 77 | 0.140 |
Why?
|
| Young Adult | 6 | 2024 | 13129 | 0.140 |
Why?
|
| Research Personnel | 1 | 2020 | 171 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 2 | 2015 | 66 | 0.140 |
Why?
|
| Anti-Obesity Agents | 1 | 2018 | 57 | 0.140 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2018 | 103 | 0.140 |
Why?
|
| Calibration | 1 | 2018 | 146 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2021 | 385 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 401 | 0.140 |
Why?
|
| Clinical Chemistry Tests | 2 | 2015 | 11 | 0.140 |
Why?
|
| Inpatients | 1 | 2021 | 496 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1684 | 0.140 |
Why?
|
| Uracil | 1 | 2017 | 31 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 649 | 0.130 |
Why?
|
| Morbidity | 1 | 2018 | 323 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1572 | 0.130 |
Why?
|
| Glycopeptides | 2 | 2014 | 43 | 0.130 |
Why?
|
| Intestines | 1 | 2020 | 357 | 0.130 |
Why?
|
| Overweight | 2 | 2018 | 557 | 0.130 |
Why?
|
| Pandemics | 2 | 2022 | 1616 | 0.130 |
Why?
|
| Biological Assay | 2 | 2015 | 123 | 0.130 |
Why?
|
| Vascular Patency | 1 | 2016 | 103 | 0.130 |
Why?
|
| Pericarditis | 1 | 2016 | 10 | 0.130 |
Why?
|
| Aortitis | 1 | 2016 | 10 | 0.130 |
Why?
|
| Vascular Grafting | 1 | 2016 | 13 | 0.130 |
Why?
|
| Marketing | 1 | 2016 | 30 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2020 | 546 | 0.130 |
Why?
|
| Cyclopropanes | 1 | 2016 | 90 | 0.130 |
Why?
|
| Uncertainty | 1 | 2016 | 128 | 0.120 |
Why?
|
| Smoking | 2 | 2021 | 1620 | 0.120 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 259 | 0.120 |
Why?
|
| Algorithms | 2 | 2020 | 1690 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 112 | 0.120 |
Why?
|
| Piperidines | 1 | 2017 | 206 | 0.120 |
Why?
|
| Down-Regulation | 1 | 2017 | 656 | 0.120 |
Why?
|
| Adiponectin | 1 | 2017 | 244 | 0.120 |
Why?
|
| France | 3 | 2019 | 33 | 0.120 |
Why?
|
| ROC Curve | 2 | 2014 | 545 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 283 | 0.120 |
Why?
|
| Simvastatin | 1 | 2015 | 61 | 0.120 |
Why?
|
| Benzaldehydes | 1 | 2014 | 8 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2025 | 1710 | 0.110 |
Why?
|
| Oximes | 1 | 2014 | 24 | 0.110 |
Why?
|
| International Cooperation | 2 | 2013 | 198 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 418 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2023 | 1070 | 0.110 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 2048 | 0.110 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1428 | 0.110 |
Why?
|
| Sleep | 1 | 2020 | 753 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2018 | 442 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2024 | 10997 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 208 | 0.100 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 70 | 0.100 |
Why?
|
| Veterans | 2 | 2022 | 1466 | 0.100 |
Why?
|
| Adolescent | 5 | 2024 | 21385 | 0.100 |
Why?
|
| Bacteria | 1 | 2020 | 854 | 0.100 |
Why?
|
| Social Media | 1 | 2016 | 157 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2024 | 412 | 0.100 |
Why?
|
| Calgranulin B | 1 | 2012 | 10 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 408 | 0.100 |
Why?
|
| Calgranulin A | 1 | 2012 | 11 | 0.100 |
Why?
|
| Blood Proteins | 1 | 2014 | 252 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 36 | 0.100 |
Why?
|
| Osteoprotegerin | 1 | 2012 | 24 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 698 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2022 | 1133 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 2 | 2023 | 178 | 0.090 |
Why?
|
| Internet | 1 | 2016 | 647 | 0.090 |
Why?
|
| Models, Biological | 1 | 2018 | 1773 | 0.090 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 48 | 0.090 |
Why?
|
| Protein Precursors | 2 | 2014 | 132 | 0.090 |
Why?
|
| Primary Prevention | 2 | 2025 | 196 | 0.090 |
Why?
|
| Femoral Artery | 2 | 2022 | 179 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2018 | 1046 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 916 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 382 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 530 | 0.080 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2009 | 2 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2023 | 404 | 0.080 |
Why?
|
| Troponin C | 1 | 2008 | 5 | 0.070 |
Why?
|
| Natriuretic Peptides | 1 | 2008 | 9 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1507 | 0.070 |
Why?
|
| Child | 3 | 2024 | 21819 | 0.070 |
Why?
|
| Exercise Test | 2 | 2025 | 625 | 0.070 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 27 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2023 | 778 | 0.070 |
Why?
|
| Death | 2 | 2020 | 119 | 0.070 |
Why?
|
| Body Weight | 2 | 2023 | 985 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 547 | 0.060 |
Why?
|
| Pregnancy | 2 | 2024 | 6729 | 0.060 |
Why?
|
| Naphthyridines | 1 | 2025 | 19 | 0.060 |
Why?
|
| Heart Ventricles | 1 | 2010 | 785 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2023 | 2375 | 0.060 |
Why?
|
| Spironolactone | 1 | 2025 | 36 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2025 | 1774 | 0.060 |
Why?
|
| Phosphocreatine | 1 | 2025 | 46 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 587 | 0.060 |
Why?
|
| Gangrene | 1 | 2024 | 10 | 0.060 |
Why?
|
| Thrombophilia | 1 | 2025 | 83 | 0.060 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2025 | 98 | 0.060 |
Why?
|
| Coronary Stenosis | 1 | 2024 | 38 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2010 | 894 | 0.050 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2024 | 57 | 0.050 |
Why?
|
| Everolimus | 1 | 2023 | 91 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3540 | 0.050 |
Why?
|
| Inhibins | 1 | 2023 | 44 | 0.050 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2022 | 15 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2022 | 47 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 245 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2025 | 610 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 66 | 0.050 |
Why?
|
| Therapeutics | 1 | 2022 | 14 | 0.050 |
Why?
|
| Animals | 5 | 2023 | 36850 | 0.050 |
Why?
|
| Sex Factors | 2 | 2021 | 2064 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 17759 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2023 | 208 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 739 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 556 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2021 | 62 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 2751 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 216 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 116 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 622 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 75 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 480 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 390 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2019 | 39 | 0.040 |
Why?
|
| Infant | 2 | 2024 | 9395 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 543 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2020 | 119 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2019 | 73 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 417 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2018 | 25 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 75 | 0.040 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 60 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2019 | 86 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2018 | 36 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2019 | 89 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 889 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 691 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 2019 | 91 | 0.040 |
Why?
|
| New Zealand | 1 | 2018 | 55 | 0.040 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 47 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 219 | 0.040 |
Why?
|
| Diuresis | 1 | 2018 | 10 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 128 | 0.040 |
Why?
|
| Sweden | 1 | 2018 | 101 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2018 | 92 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2018 | 43 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 288 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2184 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 201 | 0.030 |
Why?
|
| Machine Learning | 1 | 2022 | 488 | 0.030 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2017 | 6 | 0.030 |
Why?
|
| Logistic Models | 1 | 2022 | 2067 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 345 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2023 | 739 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 844 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 218 | 0.030 |
Why?
|
| Florida | 1 | 2017 | 103 | 0.030 |
Why?
|
| England | 1 | 2017 | 97 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 1019 | 0.030 |
Why?
|
| Insulin | 2 | 2018 | 2406 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 2829 | 0.030 |
Why?
|
| Marfan Syndrome | 1 | 2016 | 41 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 935 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 323 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 218 | 0.030 |
Why?
|
| Health Promotion | 1 | 2022 | 734 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 131 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2021 | 800 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 181 | 0.030 |
Why?
|
| Bone Density | 1 | 2019 | 487 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 976 | 0.030 |
Why?
|
| Prediabetic State | 1 | 2018 | 253 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 2412 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 354 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2019 | 376 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2015 | 106 | 0.030 |
Why?
|
| Vaccination | 1 | 2023 | 1377 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 337 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 1094 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 851 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 361 | 0.030 |
Why?
|
| Publishing | 1 | 2016 | 145 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 1066 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 1718 | 0.030 |
Why?
|
| Sodium Channel Blockers | 1 | 2014 | 24 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2014 | 57 | 0.030 |
Why?
|
| Metformin | 1 | 2018 | 330 | 0.030 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2013 | 6 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 208 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2013 | 85 | 0.030 |
Why?
|
| Massachusetts | 1 | 2014 | 172 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2016 | 351 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2012 | 24 | 0.020 |
Why?
|
| Norway | 1 | 2012 | 43 | 0.020 |
Why?
|
| Retreatment | 1 | 2012 | 72 | 0.020 |
Why?
|
| Creatinine | 1 | 2014 | 499 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2011 | 26 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2011 | 143 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 213 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 6032 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2009 | 4 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 5077 | 0.020 |
Why?
|
| Atherectomy | 1 | 2008 | 37 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 1905 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2011 | 1110 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 356 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 1127 | 0.010 |
Why?
|